Seeking AlphaThu, 25 Jun 2026 05:23:18 GMTViridian Therapeutics: A Two-Step TED Franchise With More Leverage Than The Market AppreciatesVRDN+3.12%
Seeking AlphaWed, 10 Jun 2026 04:02:19 GMTViridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptVRDN+3.12%
Seeking AlphaTue, 05 May 2026 21:31:15 GMTViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease TranscriptVRDN+3.12%
BenzingaTue, 05 May 2026 14:21:48 GMTViridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease MarketVRDN+3.12%
Investors Business DailyTue, 05 May 2026 12:00:47 GMTHow This Amgen Rival, Up 30%, Plans To Shake Its Grip In Thyroid Eye DiseaseVRDN+3.12%
Seeking AlphaThu, 02 Apr 2026 17:12:11 GMTViridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease TranscriptVRDN+3.12%
Zacks Investment ResearchWed, 01 Apr 2026 13:10:26 GMTViridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?VRDN+3.12%
